Company intelligence / Profile preview
DRI Bioscience
Miami, Florida, United Statesdribioscience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DRI Bioscience is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics for the treatment of refractory cancers. The company's lead research programs target the hypoxia-inducible factor (HIF) pathway, which plays a critical role in tumor survival, angiogenesis, and resistance to conventional therapies. By inhibiting these pathways, DRI Bioscience aims to disrupt the tumor microenvironment and improve outcomes for patients with aggressive solid tumors such as glioblastoma and pancreatic cancer. The company is currently advancing its lead candidates through lead optimization and early safety studies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on DRI Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DRI Bioscience.